BTB: Dimerix investigates new treatment for COVID-19 complications

36:29
 
Delen
 

Manage episode 330230308 series 3009792
Van MTPConnect, ontdekt door Player FM en onze gemeenschap - copyright toebehorend aan de uitgever, niet aan Player FM. Audio wordt direct van hun servers gestreamd. Klik de abonneren-knop aan om updates op Player FM te volgen of plak de feed URL op andere podcast apps.

The last few years have been dominated by the global fight against COVID-19 and research efforts continue in search of new treatments and vaccines to save lives.

Melbourne-based Dimerix Bioscience is a clinical-stage biopharmaceutical company investigating a new treatment for respiratory complications as a result of COVID 19 – which was selected for inclusion in the global WHO-endorsed clinical study REMAP-CAP investigating community-acquired pneumonia.

Through MTPConnect’s Biomedical Translation Bridge (BTB) Program, Dimerix was awarded $1 million in MRFF-funding for this COVID-19 related project.

MTPConnect host Caroline Duell catches up with Dr Robert Shepherd, Research & Development Director at Dimerix Bioscience to find out more about this potential new treatment, the benefits and challenges of being part of a unique adaptive clinical trial program and how they managed to manufacture doses for the trial during the pandemic. https://dimerix.com/
Uniquest is a Venture Partner in the BTB Program, and Cecile Francis, Uniquest’s BTB Program Project Manager joins the discussion. https://uniquest.com.au/

132 afleveringen